User:Mr. Ibrahem/Brexpiprazole

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Brexpiprazole
Clinical data
Pronunciation/brɛkˈspɪprəzoʊl/ brek-SPIP-rə-zohl
/rɛkˈsʌlti/ rek-SUL-tee
Trade namesRexulti, Rxulti
Other namesOPC-34712
AHFS/Drugs.comMonograph
MedlinePlusa615046
License data
Pregnancy
category
Routes of
administration		By mouth (tablets)
Drug classAtypical antipsychotic[2]
Legal status
Legal status
Pharmacokinetic data
Bioavailability95% (Tmax = 4 hours)[4]
Protein binding>99%
MetabolismLiver (mainly mediated by CYP3A4 and CYP2D6)
Elimination half-life91 hours (brexpiprazole), 86 hours (major metabolite)
ExcretionFeces (46%), urine (25%)
Identifiers
  • 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]quinolin-2(1H)-one
Chemical and physical data
FormulaC25H27N3O2S
Molar mass433.57 g·mol−1
3D model (JSmol)
  • O=C5/C=C\c4ccc(OCCCCN3CCN(c1cccc2sccc12)CC3)cc4N5
  • InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
  • Key:ZKIAIYBUSXZPLP-UHFFFAOYSA-N

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic used to treat schizophrenia, and major depressive disorder (MDD).[2] In schizophrenia it may be used in those over the age of 12.[2] It is taken by mouth.[5]

Common side effects include weight gain and a movement disorder known as akathisia.[2] Other side effects may include neuroleptic malignant syndrome, tardive dyskinesia, diabetes, problem gambling, and low white blood cells.[2] Use in older people with dementia increases the risk of death.[2] Safety in pregnancy is unclear.[6] It is believed to work by affecting dopamine, serotonin, and noradrenaline in the brain.[5]

Brexpiprazole was approved for medical use in the United States in 2015 and Europe in 2018.[2][5] It is not available in the United Kingdom as of 2022.[7] In the United States it costs about 1,200 USD per month as of 2022, regardless of the dose.[8]

References[edit]

  1. ^ a b "Brexpiprazole (Rexulti) Use During Pregnancy". Drugs.com. 10 February 2020. Archived from the original on 5 December 2020. Retrieved 18 August 2020.
  2. ^ a b c d e f g h i "DailyMed - REXULTI- brexpiprazole tablet". dailymed.nlm.nih.gov. Archived from the original on 11 May 2021. Retrieved 11 January 2022.
  3. ^ "Summary for ARTG Entry:273224 Rexulti brexpiprazole 4 mg film coated tablets blisters". Therapeutic Goods Administration (TGA). Retrieved 18 August 2020.{{cite web}}: CS1 maint: url-status (link)
  4. ^ "REXULTI® (brexpiprazole) Tablets, for Oral Use. Full Prescribing Information" (PDF). Rexulti (brexpiprazole) Patient Site. Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan. Archived (PDF) from the original on 5 March 2016. Retrieved 15 July 2015.
  5. ^ a b c "Rxulti". Archived from the original on 12 January 2022. Retrieved 11 January 2022.
  6. ^ "Brexpiprazole (Rexulti) Use During Pregnancy". Drugs.com. Archived from the original on 5 December 2020. Retrieved 11 January 2022.
  7. ^ "Brexpiprazole". SPS - Specialist Pharmacy Service. 10 February 2016. Archived from the original on 12 January 2022. Retrieved 11 January 2022.
  8. ^ "Brexpiprazole Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 11 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Brexpiprazole&oldid=1088632048"